Sobre el 70% de los casos se produce después de un procedimiento dental Palabras clave: osteonecrosis, bifosfonatos, osteonecrosis de los maxilares. os riscos das condições orais e sistêmicas que envolvem o uso de bifosfonatos. para tratar a estos pacientes en las distintas especialidades odontologicas. La prevalencia de avulsión dental supone del 0, % de todas las lesiones .. (58), acetazolamida (59), bifosfonatos (60,61)o derivado de la matriz del.

Author: Grotaxe Gakinos
Country: Slovenia
Language: English (Spanish)
Genre: Career
Published (Last): 27 August 2016
Pages: 60
PDF File Size: 11.20 Mb
ePub File Size: 14.78 Mb
ISBN: 819-4-17422-355-6
Downloads: 5115
Price: Free* [*Free Regsitration Required]
Uploader: Shakasida

Vidal 1C. Medina 2 y L. Hospital Universitario Puerta del Mar. Hospital de Jerez de la Frontera.

BIFOSFONATO FINAL by Fabiola González on Prezi

Bisphosphonates are widely indicated, and most therapies using bisphosphonates are given long-term, which has favored the emergence of new odontoologia adverse effects — maxillary osteonecrosis MONsevere pain, atypical fractures, stomatitis, and inflammatory eye disorders.

The goal of this paper is to review the current safety status of these drugs, and to describe the newly emerging adverse effects. Bisphosphonates may be divided up into two types according to their chemical structure and mechanism of action, as the presence or absence of nitrogen in their molecule entails differences in power.

No tests are available that allow an identification of patients at higher risk for developing MON in order to adopt appropriate preventive measures. The causal relationship of bisphosphonates with atypical fractures could not be demonstrated, but their prescription is recommended in patients recovering from recent fractures.

Nor is there any evidence that bifksfonatos may induce bone, muscle, or joint pain, but consideration must be given to the fact that pain subsides on most occasions upon bisphosphonate therapy discontinuation. No definite conclusions can be drawn to establish a causal relationship between bisphosphonate use and increased risk for AF.

The presence of other risk factors should be taken into account, and patients should be surveilled on an individual basis for the potential emergence of heart rhythm disturbances. The actuality of a higher risk for esophageal cancer in association with the use of bisphosphonates could not be confirmed. However, the FDA recommends that oral bisphosphonates should not be prescribed for patients with Barrett’s esophagus. Entre los factores de riesgo destacan: Desde entonces se han seguido publicando casos similares Sin embargo, es importante recordar que los bifosfonatos disminuyen la tasa total de fracturas.


Es probable que el tratamiento concomitante con otros medicamentos aumente el riesgo.

La toma de corticosteroides puede estar relacionada con una osteoporosis de mecanismo complejoNo se conocen los factores de riesgo ni su incidencia. En general se controla bastante bien con el tratamiento adecuado aunque su tendencia ‘natural’ es a cronificarse. Sin embargo, sigue existiendo una considerable incertidumbre en cuanto a la evidencia global.

No se pueden establecer conclusiones definitivas, debido fundamentalmente a la escasez de estudios y heterogeneidad de los mismos. Otros estudio, que utilizaba la misma base de datos que el de Green y cols. El mecanismo por el cual los bifosfonatos pueden producir estos trastornos oculares no se conoce con exactitud. Se han propuesto algunas recomendaciones para el manejo de los pacientes tratados con bifosfonatos que presentan efectos adversos oculares Tabla II. Valorar los factores de riesgo asociados que puedan favorecer los efectos adversos comentados y poner en el otro lado de la balanza el riesgo de fracturas.

An Med Interna ; Jaw bone necrosis without previous dental extractions associated with the use of bisphosphonates pamidronate and zoledronate: J Oral Pathol Med ; Farnesol and geranylgeraniol prevent activation of caspases by aminobisphosphonates: Mol Pharmacol ; From molds and macrophages to mevalonate: Calcif Tissue Int ; Breast Cancer Res ; 4: Treatment of osteoporosis odontologiz biphosphonates.

Rheum Dis Bifosfonaos North Am ; Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women.

Endocrinol Metab Clin North Am ; Alendronate has a residual effect on bone mass in postmenopausal Danish women up to 7 years after treatment withdrawal. Severely suppressed bone turnover: J Clin Endocrinol Metab ; Cyer B, Bauer DC. Oral biphosphonates and upper gastrointestinal tract problems: Mayo Clin Gifosfonatos ; Pelayo M, Agra Y.

Med Clin Barc ; The managment of Paget’s disease of bone. N Engl J Med ; Rodino MA, Shane E.

Osteonecrosis de los Maxilares Asociado a Terapia con Bifosfonatos: Situación Actual

Osteoporosis after organ transplantation. Am J Med ; Intravenous biphosphonate therapy in children with osteogenesis imperfecta. Treatment of hypercalcemia of malignancy with biphosphonates. Semin Oncol ; Severe osteomyelitis of the jaw in long-term survivors of multiple myeloma: Osteonecrosis of jaw in patient with hormone-refractory prostate cancer treated with zoledronic acid.

  ISO 4422-2 PDF

Biphosphonates for the prevention of bone metastases. Inhibition of bone resorption by alendronate and risedronate does not require osteoclast apoptosis.

The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs. Osteonecrosis de los maxilares.

Bol Inf farmacoter Navar ; 17 5: Discovery, clinical development, and therapeutic uses of bispophonates. Ann Pharmacother ; 39 4: Osteonecrosis of the jaws associated with the use of bisphosphonates: J Oral Maxillofac Surg ; Insights into material and structural basis of bone fragility from diseases associated with fractures: Endocr Rev ; Pamidronate Aredia and zoledronate Zometa induced avascular necrosis of the jaws: Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: J Clin Oncol ; Avascular jaw osteonecrosis in association with cancer chemotherapy: Hewitt C, Farah CS.

Bisphosphonate-related osteonecrosis of the jaws: Osteonecrosis of the jaws in periodontal patients with a history of bisphosphonates treatment. J Clin Periodontol ; Bisphosphanates and oral cavity avascular bone necrosis.

Osteonecrosis of the jaws asociate with use of risedronate: Cancer Invest ; Natural history of osteonecrosis of the jaw in patients with multiple myeloma. Survey of members of myeloma UK on biphosphontes associated jaw osteonecrosis. Br J Haematol ; Possible delayed onset of osteonecrosis of the jaw in association with zoledronic acid.

J Clin Pharm Ther ; Osteonecrosis of the jaw in patients with multiple myeloma treated with zoledronic acid. Bisphosphonate-induced osteonecrosis of the jaw ONJ: Incidence and risk factors in patients with breast cancer and gynecological malignancies.

Gynecol Oncol ; Osteonecrosis of the jaw as an adverse bisphosphonate event: Osteonecrosis of the jaw in patients with bone metastases treated with bisphosphonates: Mehta RS, Chwistek M. Bisphosphonates and osteonecrosis of the jaw. J Palliat Med ; Oral podium clodronate induced osteonecrosis of the jaw in a patient with myeloma.

Eur J Haematol ; A case of osteonecrosis of the jaw in a breast cancer patient with bone metastases receiving longterm treatment with bisphosphonates.

Breast Cancer ; Naveau A, Naveau B. Osteonecrosis of the jaw in patients taking bisphosphonates.